BRCA1 and ovarian cancer: Recently, our group has showed that in optimally debulked advanced ovarian cancer patients treated with platinum-based chemotherapy, low BRCA1 protein expression was significantly associated with a better progression-free survival (PFS) (median PFS was 24.7 and 16.6 months in patients with low and high BRCA1, resp.; HR = 0.56) [110].